Short Versus Long Antibiotic Duration in Streptococcus pneumoniae Bacteremia.|https://dx.doi.org/10.1093/ofid/ofae478
The 3 Ds: Depression, Dysbiosis, and Clostridiodes difficile.|https://dx.doi.org/10.1007/s12325-024-02972-0
Challenges in Liver Transplantation for Hepatocellular Carcinoma: A Review of Current Controversies.|https://dx.doi.org/10.3390/cancers16173059
Significant drop in serum C-reactive protein in patients with solid neoplasia and bacterial infection is associated with a better prognosis and identifies candidates for short-course antibiotic therapy.|https://dx.doi.org/10.1186/s12879-024-09544-1
A randomized controlled trial of efficacy and safety of Fecal Microbiota Transplant for preventing recurrent Clostridioides difficile infection.|https://dx.doi.org/10.1093/cid/ciae467
Déjà vu: Unanswered Questions about Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.|https://dx.doi.org/10.1093/cid/ciae468
[Advances in the treatment of Clostridium difficile infection in children].|https://dx.doi.org/10.7499/j.issn.1008-8830.2405055
Medial Patellofemoral Ligament Reconstruction Improves Patella Alta.|https://dx.doi.org/10.1097/BPO.0000000000002816
Clostridioides difficile infection: an update.|https://dx.doi.org/10.53854/liim-3203-3
Therapeutics involved in managing initial and recurrent Clostridium difficile infection: An updated literature review.|https://dx.doi.org/10.4292/wjgpt.v15.i5.95467
End-to-end donor screening and manufacturing controls: complementary quality-based strategies to minimize patient risk for donor-derived microbiome therapeutics.|https://dx.doi.org/10.1080/19490976.2024.2402550
Real-world effectiveness of fidaxomicin in patients at high risk of Clostridioides difficile recurrence.|https://dx.doi.org/10.1017/ash.2024.381
Dysbiosis and fecal microbiota transplant: Contemplating progress in health, neurodegeneration and longevity.|https://dx.doi.org/10.1007/s10522-024-10136-4
Rational Design of Live Biotherapeutic Products for the Prevention of Clostridioides difficile Infection.|https://dx.doi.org/10.1093/infdis/jiae470
Identification and preclinical evaluation of MMV676558 as a promising therapeutic candidate against Clostridioides difficile.|https://dx.doi.org/10.1016/j.biopha.2024.117469
Fecal microbiota spores, live-brpk (VOWST™/VOS) for prevention of recurrent Clostridioides difficile infection.|https://dx.doi.org/10.1080/17460913.2024.2403892
Gut Microbial and Metabolic Features Associated With Clostridioides difficile Infection Recurrence in Children.|https://dx.doi.org/10.1093/ofid/ofae506
Clostridium difficile infection following colon subtotal resection in a patient with gallstones: A case report and review of literature.|https://dx.doi.org/10.4240/wjgs.v16.i9.3048
A Retrospective Assessment of Guideline Adherence and Treatment Outcomes From Clostridioides difficile Infection Following the IDSA 2021 Clinical Guideline Update: Clostridioides difficile Infection.|https://dx.doi.org/10.1093/ofid/ofae524
